A novel design of a multi-antigenic, multistage and multi-epitope vaccine against Helicobacter pylori: An in silico approach

Meza, Beatriz; Ascencio, Felipe; Sierra-Beltrán, Arturo P.; Torres, Javier; Angulo, Carlos

doi:10.1016/j.meegid.2017.02.007

Cited by 157 publications

(105 citation statements)

References 46 publications

Supporting

Mentioning

104

Contrasting

Order By: Relevance

“…The knowledge of secondary and tertiary structures of the target protein is essential in vaccine design 39, 40 . Secondary structure analysis of the CoV-RMEN indicated that the protein consisted of 43.2% alpha helix, 67.4% beta sheet, and 12% turns with only 2 residues disordered.…”

Section: Discussionmentioning

confidence: 99%

“…Secondary structure analysis of the CoV-RMEN indicated that the protein consisted of 43.2% alpha helix, 67.4% beta sheet, and 12% turns with only 2 residues disordered. Natively unfolded protein regions and alpha-helical and beta sheet peptides have been reported to be important forms of structural antigens 21, 40 . These two structural forms (secondary and tertiary), when tested as the synthetic peptides, have the ability to fold into their native structure,hence, could be recognized by naturally induced antibodies in response to infection 2 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2 etiologic agent of global pandemic COVID-19: anin silicoapproach

Rahman

Hoque

Islam

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2 etiologic agent of global pandemic COVID-19: anin silicoapproach

Rahman

Hoque

Islam

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…[22,23]. Thus, they have been broadly applied for a range of viral, bacterial, and parasitic diseases [24][25][26]. The most important factors for designing a multi-epitope vaccine are predicting and screening the functional neutralizing B cell epitopes and species-restricted T cell epitopes [27,28].…”

Section: Introductionmentioning

confidence: 99%

A Recombinant La Sota Vaccine Strain Expressing Multiple Epitopes of Infectious Bronchitis Virus (IBV) Protects Specific Pathogen-Free (SPF) Chickens against IBV and NDV Challenges

et al. 2019

View full text Add to dashboard Cite

Infectious bronchitis (IB) and Newcastle disease (ND) are two major infectious diseases that are a threat to the domestic poultry industry. In this study, we successfully generated a recombinant LaSota candidate vaccine strain, rNDV-IBV-T/B, which expresses a short, synthetic, previously identified IBV S1 multi-epitope cassette using the reverse genetic system. The recombinant virus was propagated in nine-day-old embryonated chicken eggs for 20 passages and genetic stability was confirmed by whole genome DNA sequencing. The recombinant virus had a hemagglutination (HA) titer of 2 10 , mean death time (MDT) of 118 hours, and intracerebral pathogenicity index (ICPI) of 0.05. None of these were significantly different from the parental Newcastle disease virus (NDV) LaSota strain (p > 0.05). Vaccination of white leghorn chickens at one day of age with 10 6 EID 50 rNDV-IBV-T/B provided 90% protection against virulent IBV M41 challenge at three weeks of age, which was significantly higher than the protection of the control group vaccinated with phosphate-buffered saline (PBS) (p < 0.05). The ciliostasis scores of rNDV-IBV-T/B-vaccinated and LaSota-vaccinated groups were 4.2 and 37.6, respectively, which indicated that rNDV-IBV-T/B vaccination reduced the pathogenicity of IBV toward the trachea. Furthermore, real-time RT-PCR assay showed that the rNDV-IBV-T/B vaccination resulted in low levels of viral load (647.80 ± 49.65 RNA copies) in the trachea four days post-challenge, which is significantly lower than groups vaccinated with PBS (8591.25 ± 311.10 RNA copies) or LaSota (7742.60 ± 298.50 RNA copies) (p < 0.05). Meanwhile, the same dose of rNDV-IBV-T/B vaccination provided complete protection against velogenic NDV F48E9 challenge. These results demonstrate that the rNDV-IBV-T/B strain is a promising vaccine candidate to control both IB and ND simultaneously. Furthermore, epitope-based live vector vaccines provide an alternative strategy for the development of cost-effective and, broadly, cross-protective vaccines.

show abstract

“…Successful vaccine development is a complex process, depending on many factors including choice of antigens, epitopes, adjuvants, delivery systems, and the administration route. No human trials of Helicobacter vaccines were published during the past year; however, several H. pylori articles were published on a variety of approaches, including using bioinformatics to improve the immunogenicity of H. pylori components . Several groups investigated Helicobacter vaccines using mouse models, however, very few tested their protective efficacy.…”

Section: Vaccinesmentioning

confidence: 99%

“…No human trials of Helicobacter vaccines were published during the past year; however, several H. pylori articles were published on a variety of approaches, including using bioinformatics to improve the immunogenicity of H. pylori components. [41][42][43] Several groups investigated Helicobacter vaccines using mouse models, however, very few tested their protective efficacy. The most commonly investigated vaccine antigens were urease B, 44,45 neuraminyllactose-binding hemagglutinin (HpaA), [46][47][48] and H. pylori whole cells or lysates.…”

Section: Immunization and Vaccinesmentioning

confidence: 99%

Helicobacter: Inflammation, immunology and vaccines

2017

View full text Add to dashboard Cite

Helicobacter pylori is usually acquired in early childhood and the infection persists lifelong without causing symptoms. In a small of cases, the infection leads to gastric or duodenal ulcer disease, or gastric cancer. Why disease occurs in these individuals remains unclear, however the host response is known to play a very important part. Understanding the mechanisms involved in maintaining control over the immune and inflammatory response is therefore extremely important. Vaccines against H. pylori have remained elusive but are desperately needed for the prevention of gastric carcinogenesis. This review focuses on research findings which may prove useful in the development of prognostic tests for gastric cancer development, therapeutic agents to control immunopathology, and effective vaccines.

show abstract

A novel design of a multi-antigenic, multistage and multi-epitope vaccine against Helicobacter pylori: An in silico approach

Cited by 157 publications

References 46 publications

Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2 etiologic agent of global pandemic COVID-19: anin silicoapproach

Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2 etiologic agent of global pandemic COVID-19: anin silicoapproach

A Recombinant La Sota Vaccine Strain Expressing Multiple Epitopes of Infectious Bronchitis Virus (IBV) Protects Specific Pathogen-Free (SPF) Chickens against IBV and NDV Challenges

Helicobacter: Inflammation, immunology and vaccines

Contact Info

Product

Resources

About